THE PREVALENCE OF ARTERIAL HYPERTENSION AND ITS RISK FACTORS TOWARD HIV-POSITIVE PERSONS IN FERGANA VALLEY

Mirzoulugbek Mirsaydullaev, Nematjon Mamasaliev

Abstract


Background: The data on the prevalence of arterial hypertension (AH) in patients with HIV/AIDS vary. Even though some authors have reported higher prevalence of high blood pressure  and systemic arterial hypertension in this group, compared to the prevalence of AH in subjects without infection, other studies have found similar prevalence of AH between men and women with HIV and individuals without the infection. In Uzbekistan such researches were not conducted yet.

Objective: Evaluate the prevalence of prevalence of arterial hypertension and its risk factors at the HIV-positive persons of Fergana Valley of Uzbekistan.

Methods:  A cross-sectional study aligned to a cohort of patients with HIV/AIDS. The study considered hypertension at levels ≥ 140/90 mmHg or use of antihypertensive drugs and pre-hypertension at levels > 120/80 mmHg.

Results: Out of this total, 138 patients (48%) were male and 149 were female (52%); 65% of them were 40 years-old or younger, and other 35% were over 40 years of age. Among the individuals evaluated, 184 (64.1%) had blood pressure within the normal range, 62 (21.6%) were considered prehypertensive, and 41 (14.3%) were considered hypertensive. Twenty five patients (61%) knew they had hypertension, and 9 of them (36.0%) used antihypertensive medication on a continuous basis. The blood pressure levels were controlled in only 5 (20.0%) patients that knew that they were hypertensive.

Conclusion: Among HIV-infected persons, 21.6% were considered prehypertensive, and 14.3% were considered hypertensive. It is important to warn clinicians who provide care to HIV/AIDS patients that such patients are not only individuals infected with a potentially fatal virus, but, despite the benefit of new antiretroviral therapies, they are also patients whose prognosis may be affected by comorbidities, such as hypertension.


Keywords


arterial hypertension, HIV-positive persons, risk factors.

Full Text:

PDF

References


Aoun, S., & Ramos, E. (2000). Hypertension in the HIV-infected patient. Current Hypertension Reports, 2, 478-81.

Baekken, M., Os, I., Sandvik, L., & Oektedalen, O. (2008). Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. Journal of Hypertension, 26 (11), 2126-33.

Baekken, M., Os, I., Sandvik, L., & Oektedalen, O. (2008). Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. Journal of Hypertension, 26, 2126–33.

Bergersen, B.M., Sandvik, L., Bruun, J.N., & Tonstad, S. (2004). Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. European Journal of Clinical Microbiology and Infectious Diseases, 23 (8), 625-30.

Bergersen, B.M., Sandvik, L., Dunlop, O., Birkeland, K., & Bruun, J.N. (2003). Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIVnegative controls: results from a Norwegian study of 721 patients. European Journal of Clinical Microbiology and Infectious Diseases, 22, 731-6.

Besson, H., Ekelund, U., & Luan, J. (2009). A cross-sectional analysis of physical activity and obesity indicators in European participants of the EPIC-PANACEA study. International Journal of Obesity, 33, 497-506.

Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, Jr. J.L., Jones, D.W., Materson, B.J., Oparil, S., Wright, J.T., & Roccella, E.J. (2003). The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension, 42 (6), 1206-52.

Chow, D.C., Souza, S.A., Chen, R., Richmond-Crum, S.M., Grandinetti, A., & Shikuma, C. (2003). Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clinical Trials, 4 (6), 411-6.

Coloma Conde, A.G., Alvarez Albarrán, M., Roca-Cusachs Coll, A., Domingo Pedrol, P., & Puig Campmany, M. (2008). Prevalence of arterial hypertension and lipid profile in HIV patients. Medicina Clinica (Barcelona), 131, 681-4.

Crane, H.M., Van Rompaey, S.E., & Kitahata, M.M. (2006). Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS, 20 (7), 1019-26.

Dube, M.P., Lipshultz, S.E., Fichtenbaum, C.J., Greenberg, R., Schecter, A.D., & Fisher, S.D. (2008). Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation, 118, 36-40.

Dusek, J.A., Hibberd, P.L., Buczynski, R.N., Chang, B.H., Dusek, K.C., & Johnston, J.M. (2008). Stress management versus lifestyle modification on systolic hypertension and medication elimination: a randomized trial. Journal of Alternative and Complementary Medicine, 14 (2), 129-38.

Flegal, K.M., Carroll, M.D., Ogden, C.L., & Curtin, L.R. (2010). Prevalence and trends in obesity among US adults, 1999–2008. JAMA, 303, 235–241.

Friis-Møller, N., Reiss, P., Sabin, C.A., Weber, R, D´Arminio Monforte, A., & El-Sadr, W. (26 April. 2007). The D:A:D study group. Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. The New England Journal of Medicine, 356, 1723-35.

Gazzaruso, C., Bruno, R., Garzaniti, A., Giordanetti, S., Fratino, P., Sacchi, P., & Filice, G. (2003). Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. Journal of Hypertension, 21, 1377-82.

Gilmore, A.B., Pomerleau, J., McKee, M., Rose, R., Haerpfer, C.W., Rotman, D., & Tumanov, S. (2004). Prevalence of smoking in 8 countries of the former Soviet Union: results from the Living Conditions, Lifestyles and Health Study. American Journal of Public Health, 94, 2177–87.

Hadigan, C., Meigs, J.B., Corcoran, C., Rietschel, P., Piecuch, S., Basgoz, N., Davis, B., Sax, P., Stanley, T., Wilson, P.W., D'Agostino, R.B., & Grinspoon, S. (2001). Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystropy. Clinical Infectious Diseases, 32, 130–9.

Hogg, R., Lima, V., Sterne, J.A., Grabar, S., Battegay, M., Bonarek, M., D'Arminio Monforte, A., Esteve, A., Gill, M.J., Harris, R., Justice, A., Hayden, A., Lampe, F., Mocroft, A., Mugavero, M.J., Staszewski, S., Wasmuth, J.C., van Sighem, A., Kitahata, M., Guest, J., Egger, M., & May, M. (2008). Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet; 372:293-9.

International Physical Activity Questionnaire, IPAQ. Guidelines for data processing and analysis of the International Physical Activity Questionnaire – Short and Long Forms. (2005). http:// www.ipaq.ki.se/scoring.pdf.

Jenei, Z., Páll, D., Katona, E., Kakuk, G., & Polgár, P. (2002). The epidemiology of hypertension and its associated risk factors in the city of Debrecen, Hungary. Public Health, 116 (3), 138-44.

Khalsa, A., Karim, R., Mack, W.J., Minkoff, H., Cohen, M., Young, M., Anastos, K., Tien, P.C., Seaberg, E., & Levine, A.M. (2007). Correlates of prevalent hypertension in a large cohort of HIV-infected women: Women’s Interagency HIV Study. AIDS, 21 (18), 2539-41.

Mary-Krause, M., Cotte, L., Simon, A., Partisani, M., & Costagliola, D. (2003). Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS, 17, 2479-86.

Okubo, Y., Suwazono, Y., Kobayashi, E., & Nogawa, K. (2001). Alcohol consumption and blood pressure change: 5-year follow-up study of the association in normotensive workers. Journal of Human Hypertension, 15 (6), 367-72.

Palacios, R., Santos, J., García, A., Castells, E., González, M., Ruiz, J., & Márquez, M. (2006). Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients: a prospective study in a cohort of naive patients. HIV Medicine, 7 (1), 10-5.

Pickering, T.G. (2003). Lifestyle modification and blood pressure control: is the glass half full or half empty? JAMA, 289 (16), 2131-2.

Sattler, F.R., Qian, D., Louie, S., Johnson, D., Briggs, W., DeQuattro, V., & Dube, M.P. (2001). Elevated blood pressure in subjects with lipodystrophy. AIDS, 15, 2001–10.

Thiébaut, R., El-Sadr, W.M., Friis-Møller, N., Rickenbach, M., Reiss, P., & Monforte, A.D. (2005). Data Collection of Adverse events of anti-HIV Drugs Study Group. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antiviral therapy, 10 (7), 811-23.

WHO Report on the Global Tobacco Epidemic (2013).

Winston, J., & Klotman, P.E. (1998). HIV-associated nephropathy. Mount Sinai Journal of Medicine, 65, 27-32.

Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., & Lanas, F. (2004). Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): a case control study. Lancet, 364, 937-52.




DOI: http://dx.doi.org/10.12955/emhpj.v8i1.672

Refbacks

  • There are currently no refbacks.


Print ISSN 1804-5804, Online ISSN 1804-9702

(c) 2018 CBU,o.p.s.